Skip to main content
. 2021 Mar;10(3):852–860. doi: 10.21037/gs-20-871

Figure 3.

Figure 3

Overall survival based on the baseline inflammatory biomarker values. (A) The median overall survival (OS) was 4.2 [95% confidence interval (CI): 1.1–10.3] months in patients with baseline neutrophil-to-lymphocyte ratio (NLR) ≤4.5 and 3.1 (95% CI: 1.1–8.3) months in patients with baseline NLR >4.5, respectively (P=0.681). (B) The median OS was 4.2 (95% CI: 1.1–7.8) months in patients with baseline platelet-to-lymphocyte ratio (PLR) ≤169.9 and 3.9 (95% CI: 0.6–8.3) months in patients with baseline PLR >169.9, respectively, (P=0.822) [with baseline NLR >2.6, respectively (P=0.421) (C)].